Thyrocare Technologies Ltd

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming that the entire holding of the company's shares are in demat form and no requests for rematerialisation were received during the quarter.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has submitted copies of newspaper publications for notice of postal ballot. The company has completed sending postal ballot notices, and the e-voting period has been intimated. The information is also available on the company's website.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced a Postal Ballot Notice for seeking approval of the members by means of remote electronic voting for two resolutions: approval for purchase of land and building from Nueclear Healthcare Limited and approval for sale or divestment of Company's investment in the entire shareholding of Nueclear Healthcare Limited.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has granted 1,92,000 employee stock options at an exercise price of Rs. 10/- per option under the Thyrocare Employee Stock Option Scheme.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced the closure of its trading window under SEBI's insider trading regulations, effective from October 1, 2026, and will reopen 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 10(6) of SEBI (SAST) Regulations, 2011, regarding the amalgamation of Docon Technologies Private Limited with API Holdings Limited, resulting in API acquiring 51.02% of Thyrocare's paid-up share capital.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has published newspaper advertisements regarding the transfer of equity shares to the Investor Education and Protection Fund, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from API Holdings Ltd, indicating a potential change in shareholding or acquisition.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced that the Hon'ble NCLT, Mumbai Bench, has sanctioned the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited. The Scheme shall become operative upon the Effective Date, which is the date when all conditions precedent are completed or duly waived.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from Catalyst Trusteeship Limited, confirming the complete discharge of all obligations under the Non-Convertible Debentures (NCDs) and the Transaction Documents. The NCDs, aggregating to INR 1,700 crore, were secured by a pledge of equity shares representing 60.92% of the equity share capital of the Company held by Docon. Upon full redemption and repayment of the NCDs, the pledge has been fully released.

Thyrocare Technologies Ltd

Catalyst Trusteeship Limited, acting as Debenture Trustee, has released the pledge on 7,94,69,696 equity shares of Thyrocare Technologies Ltd after the full repayment and redemption of Non-Convertible Debentures.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd & PACs.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from Docon Technologies Private Limited, its promoter, regarding the release of a pledge over 7,94,69,696 equity shares of the company. The pledge was created due to the repayment of non-convertible debentures issued by API Holdings Limited, the ultimate holding company of the company.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from HSBC Mutual Fund, indicating a potential change in shareholding.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd on August 13, 2026.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd and PAC regarding a potential acquisition.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of pledge on 7,94,69,696 equity shares of the company. The pledge was created to secure the obligations of API Holdings Limited, the holding company, in respect of facilities availed by API through the issuance of non-convertible debentures. The debentures have been fully redeemed and repaid, resulting in the release of the pledge.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from ICICI Prudential Mutual Fund, indicating a potential change in shareholding.

Thyrocare Technologies Ltd

Catalyst Trusteeship Limited, acting as Debenture Trustee for API Holdings Limited, has released a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited, resulting in a 10.99% stake in the company.